OCUL Ocular Therapeutix, Inc.
USHealthcareAs of 2026-07-09 16:00
Why OCUL matters now
Ocular Therapeutix, Inc. (OCUL) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.54 with +2.63% on the session and $2.31B in market capitalization; recent performance reads 1-month +18.02% and YTD -22.32%.
The latest financial table shown here is Q1 2026, with revenue of $10.8M, net income of $-88.6M, and EPS of $-0.40. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.7%.
The latest indexable market news headline is "Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Dugel Pravin filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.63
P/S
39.68
EV/EBITDA
-5.39
DCF Value
$-0.63
FCF Yield
-11.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.2%
Operating Margin
-575.4%
Net Margin
-558.2%
ROE
-64.6%
ROA
-39.7%
ROIC
-43.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.8M | $-88.6M | $-0.40 |
| Q4 2025 | $13.3M | $-64.7M | $-0.29 |
| FY 2025 | $51.8M | $-265.9M | $-1.42 |
| Q3 2025 | $14.5M | $-69.4M | $-0.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$28.33
Target (Median)
$30.00
Target Range
$25.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.90
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.